Gilead says additional data on remdesivir shows improved clinical recovery
Findings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.
A LAB technician works on investigational coronavirus disease treatment drug Remdesivir at Eva Pharma Facility in Cairo, Egypt, in June(photo credit: AMR ABDALLAH DALSH / REUTERS)ByREUTERS